Corvus Pharmaceuticals' stock plummeted ~40% after Phase 1 data for soquelitinib in atopic dermatitis showed mixed results, raising concerns about its efficacy. Phase 1 data for soquelitinib in AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback